Neal Shore, MD, discusses the complexity of prostrate cancer and factors to consider when determining management strategies.
Back
Advanced Prostate Cancer: PSMA-Targeted Radioligand Therapies
Advanced Prostate Cancer: PSMA-Targeted Radioligand Therapies
Episodes
All
All
A discussion of phenotypic and genotypic biomarkers found in prostate cancer and their implications.
An overview of the diagnostic and therapeutic applications of PSMA in prostate cancer is presented.
Dr Neal Shore explains the clinical implications of PSMA PET scans in advanced prostate cancer.
Results of the phase 3 VISION study of 177Lu-PSMA PET in advanced prostate cancer are described.
Highlights of potential future applications of PSMA ligand–directed therapies in prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
4
Dr Garg on a Phase 3 Study of Proton Therapy in Head and Neck Cancer
5